Applied Health Research Centre Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2013
NCT01742117
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Applied Health Research Centre

Active Ingredients

Drugs in Phase 4 Trials (4)

clopidogrel (plavix) (1 trial)

empagliflozin (jardiance) (1 trial)

evolocumab (repatha) (1 trial)

ticagrelor (brilinta) (1 trial)

Drugs in Phase 3 Trials (1)

tranexamic acid (cyklokapron) (1 trial)

Drugs in Phase 2 Trials (2)

favipiravir (1 trial)

fluoxetine (prozac) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Atherosclerosis (Phase 4)

Brain Diseases (Phase 2)

Brain Infarction (Phase 2)

Brain Ischemia (Phase 2)

Cardiovascular Diseases (Phase 4)

Central Nervous System Diseases (Phase 2)

Cerebral Infarction (Phase 2)

Cerebrovascular Disorders (Phase 2)

Coronary Artery Disease (Phase 4)

Hypertrophy (Phase 4)

Hypertrophy, Left Ventricular (Phase 4)

Infarction (Phase 2)

Nervous System Diseases (Phase 2)

Stroke (Phase 2)

Vascular Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 7